Ichim TE, Zheng X, Suzuki M, Kubo N, Zhang X, Min LR, Beduhn ME, Riordan NH, Inman RD, Min WP.
Abstract
Background: Immunotherapy offers the promise of antigen-specific suppression of pathological immune responses in conditions such as autoimmunity and organ transplantation. Substantial advances have been made in recent years in terms of understanding basic immunological mechanisms of autoreactivity, as well as clinically implementing immune-based therapies that are antigen nonspecific. Objective: To provide an integrated overview of the current state of the art in terms of antigen-specific tolerance induction, as well as to predict future directions for the field. Methods: Examples of successes and failures of antigen-specific immunotherapy were sought. Particular attention was paid to the well-established collagen II-induced model of arthritis. Results/conclusions: Previous failures of antigen-specific immunotherapy were associated with lack of identification of clinically relevant antigens, as well as inappropriate tolerogenic methodologies. The advances in proteomics combined with novel gene-specific immune modulatory techniques place today’s translational researchers in a unique position to tackle the problem of antigen-specific immunotherapeutic protocols.
The Stem Cell Institute has integrated Intranasal MTF Therapy into its autism protocol:
MTF therapy features exosomes and over 300 beneficial molecules
Works in synergy with our stem cells
Offers anti-inflammatory and regenerative effects
Delivered in an easy-to-administer aerosol format via the nose
To discover more about MTF and its benefits, click here
We use cookies to ensure that we give you the best experience on our website. To find out more about cookies and how we use them on this site, see our privacy policy.AcceptPrivacy Policy